54 related articles for article (PubMed ID: 29776943)
1. An Unexpected Cause of Lung Disease Identified After Lung Transplantation.
Self A; Afshar K; Kafi A; Yung G; Golts E; Lin CM
Chest; 2023 Oct; 164(4):e111-e115. PubMed ID: 37805248
[TBL] [Abstract][Full Text] [Related]
2. Diffuse systemic sclerosis managed with ayurvedic treatment modalities - A case report.
Pandit RK
J Ayurveda Integr Med; 2024 May; ():100883. PubMed ID: 38760244
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate-induced colitis in a patient with lupus nephritis: a case report and review of the literature.
Alakkas Z; Gari AM; Makhdoum S; AlSindi EA
J Med Case Rep; 2024 May; 18(1):229. PubMed ID: 38689344
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate Induced Colitis: One-year Post-kidney Transplantation.
Al Saadi W; Al Salmi I; Mohammed E; Al Ajmi Z; Hannawi S
Oman Med J; 2023 Mar; 38(2):e489. PubMed ID: 37132007
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate-Induced Colitis in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients.
Schmitt MM; Ferré EMN; De Melo MS; Cooper MA; Quezado MM; Heller T; Lionakis MS
JPGN Rep; 2021 Nov; 2(4):e131. PubMed ID: 35425944
[TBL] [Abstract][Full Text] [Related]
6. Secondary causes of inflammatory bowel diseases.
Ghouri YA; Tahan V; Shen B
World J Gastroenterol; 2020 Jul; 26(28):3998-4017. PubMed ID: 32821067
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate-induced Colitis: A Case Report with Focused Review of Literature.
Farooqi R; Kamal A; Burke C
Cureus; 2020 Jan; 12(1):e6774. PubMed ID: 32117661
[TBL] [Abstract][Full Text] [Related]
8. Colitis and Pancreatitis in a Patient with Systemic Lupus Erythematosus: Due to Disease or to Drug?
Paleti S; Yarlagadda B; Gremida A; Aziz M; Hanson J; McCarthy D
Dig Dis Sci; 2018 Sep; 63(9):2206-2209. PubMed ID: 30069857
[No Abstract] [Full Text] [Related]
9. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
11. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
[TBL] [Abstract][Full Text] [Related]
12. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil-induced colitis in a patient with systemic sclerosis.
Moroncini G; Benfaremo D; Mandolesi A; Gabrielli A
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29776943
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
